|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Washington |
|---|---|
| Collaborators: |
National Heart, Lung, and Blood Institute (NHLBI) National Institute of Neurological Disorders and Stroke (NINDS) United States Army Medical Research and Material Command Canadian Institutes of Health Research (CIHR) Canadian Department of National Defense Heart and Stroke Foundation of Canada |
| Information provided by: | University of Washington |
| ClinicalTrials.gov Identifier: | NCT00316004 |
Purpose
The purpose of this study is to determine if hypertonic saline with and without dextran can improve neurologic outcomes in victims of severe traumatic brain injury (TBI).
Injury and lost blood from trauma can cause your body to go into shock (low blood pressure related to blood loss). This decreased blood flow can lead to organ damage. In order to restore the blood pressure and blood flow, the medics give fluids into the patients' veins as soon as possible. This is called "resuscitation". The fluid most commonly used is "isotonic" or one that is the same salt concentration as the blood. The investigators are trying to determine if infusing a "hypertonic" fluid or one more concentrated than the blood can increase the blood pressure and restore blood flow more efficiently. The hypertonic fluids they are using are called hypertonic saline with dextran (HSD) and hypertonic saline (no dextran). Hypertonic saline is a salt solution that is slightly more concentrated than blood. Dextran is a sugar solution.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain Injuries, Traumatic |
Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD) Drug: 7.5% Hypertonic Saline (HS) Drug: 0.9% Normal Saline (NS) |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase 3 Study of Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI) |
| Enrollment: | 1331 |
| Study Start Date: | May 2006 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 7.5% hypertonic saline/6% dextran (HSD)
250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
|
Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD)
250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Other Name: RescueFlo
|
|
Experimental: 7.5% hypertonic saline (HS)
250 ml intravenous bolus administration of 7.5% hypertonic saline
|
Drug: 7.5% Hypertonic Saline (HS)
250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
|
|
Placebo Comparator: 0.9% normal saline (NS)
250 ml intravenous bolus administration of 0.9% saline
|
Drug: 0.9% Normal Saline (NS)
250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
|
To determine if prehospital administration of 7.5% Hypertonic Saline in 6% Dextran-70 (HSD) OR 7.5% Hypertonic Saline (HS) compared to current standard therapy with NS as an initial resuscitation fluid affects neurological outcome following severe traumatic brain injury.
Trauma is the leading cause of death among North Americans between the ages of 1 and 44 years. The majority of these deaths result from hypovolemic shock or severe brain injury. Patients in hypovolemic shock develop a state of systemic tissue ischemia then a subsequent reperfusion injury at the time of fluid resuscitation. Conventional resuscitation involves the IV administration of a large volume of isotonic or slightly hypotonic (lactated ringers, LR) solutions beginning in the pre-hospital setting. Although not conclusive, prior studies have suggested that alternative resuscitation with hypertonic saline (7.5%) solutions may reduce morbidity or mortality in these patients. Furthermore, hypertonic fluids may have specific advantages in the brain-injured patient, as they may aid in the rapid restoration of cerebral perfusion and prevent extravascular fluid sequestration, thereby limiting secondary brain injury. In addition, recent studies have demonstrated that hypertonicity significantly alters the activation of inflammatory cells, an effect that may reduce subsequent organ injury from ischemia-reperfusion and decrease nosocomial infection.
This study is a randomized, double-blind, three-arm placebo controlled trial designed to evaluate the clinical outcome of trauma patients with severe TBI as manifested by a pre-hospital GCS of 8 or less. Patients will be randomized to a single 250cc IV dose of 7.5% saline in 6% Dextran-70 (HSD), 7.5% saline (HS) or normal saline as the initial fluid for pre-hospital resuscitation. No additional interventions will occur once the patient is admitted to the hospital. In hospital data collection will last up to 28 days. Patients will have neurologic outcome measurements at discharge, 1 month post discharge, and 6 months post injury. Enrollment will be restricted to age ≥ 15 years or ≥ 50 kg if age is unknown.
Eligibility| Ages Eligible for Study: | 15 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Age 15 years or older or 50 kg or more
Exclusion Criteria:
Contacts and Locations| United States, Alabama | |
| Alabama Resuscitation Center, University of Alabama | |
| Birmingham, Alabama, United States, 35249 | |
| United States, California | |
| Orange County/UC Irvine | |
| Orange, California, United States, 92868 | |
| UCSD-San Diego Resuscitation Research Center | |
| San Diego, California, United States, 92103 | |
| United States, Iowa | |
| Iowa Resuscitation Network, University of Iowa Carver College of Medicine | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Oregon | |
| Portland Resuscitation Outcomes Consortium, Oregon Health & Sciences University | |
| Portland, Oregon, United States, 97239 | |
| United States, Pennsylvania | |
| The Pittsburgh Resuscitation Network, University of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Tennessee | |
| The Regional Medical Center at Memphis | |
| Memphis, Tennessee, United States, 38103 | |
| United States, Texas | |
| Dallas Center for Resuscitation Research, University of Texas Southwestern Medical Center | |
| Dallas, Texas, United States, 75390 | |
| United States, Washington | |
| Seattle-King County Center for Resuscitation Research, University of Washington | |
| Seattle, Washington, United States, 98195 | |
| United States, Wisconsin | |
| Milwaukee Resuscitation Network, Medical College of Wisconsin | |
| Milwaukee, Wisconsin, United States, 53226 | |
| Canada, Ontario | |
| University of Ottawa/University of British Columbia Collaborative RCC, Ottawa Health Research Institute | |
| Ottawa, Ontario, Canada, K1Y4E9 | |
| Toronto Regional Resuscitation Research Out-of-Hospital Network, University of Toronto | |
| Toronto, Ontario, Canada, M5B1W8 | |
| Study Chair: | Myron L Weisfeldt, MD | Resuscitation Outcomes Consortium |
More Information
| Responsible Party: | Gerald Van Belle, PhD/Principal Investigator, Resuscitation Outcomes Consortium Data Coordinating Center |
| ClinicalTrials.gov Identifier: | NCT00316004 History of Changes |
| Other Study ID Numbers: | 28226-A - IND 12505, 5U01HL077863-05, IND #12505 TBI cohort |
| Study First Received: | April 17, 2006 |
| Results First Received: | February 11, 2011 |
| Last Updated: | May 16, 2011 |
| Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board; Canada: Ethics Review Committees; Canada: Health Canada |
|
Traumatic Brain injury |
|
Brain Injuries Brain Diseases Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries |
Dextrans Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Plasma Substitutes Blood Substitutes |